“These things don’t have to be lonely crusades, but they are. Everyone is on their own right now.” Onno Faber and @rarebasepbc are a mission to remake the dysfunctional rare disease research space. buff.ly/3CoXeuP

Next week our CSO, Chris Moxham, PhD, will give a showcase talk titled “Accelerating a Path Forward for #RareDisease #DrugDiscovery” Precision Medicine World Conference on January 27, 2023 in Santa Clara, CA. We are excited to share our insights on scalable approaches for precision medicine #PMWC23

Our #precisionmedicine platform Function identifies #drugrepurposing candidates that have the potential to target the root cause biology of rare genetic diseases. Discover how we identify these candidates based on common types of genetic variants: rarebase.org/post/how-does-…

Honored to be working with SynGAP Research Fund (SRF) on drug discovery for SYNGAP1 related disorders with @rarebasepbc. Thanks Mike Graglia 🌻 and Ashley S. Evans for all you do for the community!

Tomorrow is International Day of Women and Girls in Science 🧬🔬🚀 We are grateful to all the women on the Rarebase team for your tireless work to foster partnerships with patient organizations and drive our precision medicine research forward for the #raredisease community.

We are committed to making a difference in the lives of those affected by rare diseases and we look forward to supporting #RareDiseaseDay next week. Sign up for our newsletter to follow our journey: eepurl.com/hKNGWr

At Rarebase, we are filling the void in rare disease drug discovery to meet the urgent unmet needs of the rare disease community. This #RareDiseaseDay, learn how our precision medicine platform is advancing the hunt for new therapies: rarebase.org/post/3-700-dis…

We sat down with our Scientific Founder and Advisor, Elizabeth Iorns, PhD, to dive into the science and technology behind the Rarebase drug discovery strategy. Read more here: rarebase.org/post/reimagini…

Our discovery research team has been gearing up for compound testing in our Preclinical Stage! Our wild-type stem cells are thawed and ready for expansion and differentiation into neurons for concentration-response studies with Function-identified drug repurposing candidates.

Join us in recognizing #CACNA1A Awareness Day on March 19th! At Rarebase, we partner with the patient organization Miren's Marathon at the Rare Village Foundation in support of those affected by CACNA1A-related conditions. Together, we build a path forward for rare diseases.

Neurodevelopmental disorders make up 77% of our current drug discovery portfolio. This National Developmental Disabilities Awareness Month, let's champion support & inclusion for affected individuals with the rare disease community. #DDAM2023

In our latest podcast, Director of High Throughput Biology, Joe Bellucci, PhD, walks us through advances in high-throughput screening and next-generation sequencing that have enabled tailored and scalable approaches to rare disease research. Listen here: spotifyanchor-web.app.link/e/4QnJYQo3nyb

Rarebase has generated a premier drug screening dataset that maximizes efficiency in drug hunting for rare neurological diseases. Learn more about our breakthrough approach to meet the urgent needs of the #raredisease patient community: rarebase.org/post/how-the-r…

Our Director of Software Engineering, Clayton Mellina, believes a patient-centered approach, coupled with breakthrough technologies in machine learning and high-throughput biology, will drive a revolution in human health. Read more of our conversation: rarebase.org/post/unleashin…

We were honored to invite Ashlee Vance to Transcripta Bio to share our story and how we are charting a faster path in drug discovery to create better lives for people around the world. bloomberg.com/news/articles/…

As part of nature’s Biopharma Dealmakers, Transcripta Bio was featured for its pioneering work in AI-powered innovation for drug discovery. #TranscriptaBio #Biopharmadealmakers #Innovation nature.com/articles/d4374…